P&G Stock Stalls at $143 as Restructuring Costs Weigh on Outlook

Procter & Gamble stock remains stable at around $143 as investors weigh the benefits of its strong fiscal 2026 results against the costs of a significant restructuring program. The company's mid-single-digit revenue growth and substantial net profit of $16.1 billion in the last fiscal year are impressive, but the planned cost-cutting measures, which will reshape the consumer-products portfolio through fiscal 2027, could impact projected organic sales growth.

The restructuring plan, expected to cost between $1 billion and $1.6 billion before tax over roughly two years, includes streamlining brands, formats, and marketing methods. This may reduce projected organic sales growth for the period by 0.3 to 0.5 percentage points, according to recent reports. However, Procter & Gamble has highlighted that most restructuring actions should be completed by the end of fiscal 2027.

Despite some divergence in valuation views, with a consensus price target of $161.19 and a discounted cash flow-derived intrinsic value estimate near $90, investors are cautiously optimistic about the company's long-term prospects. Procter & Gamble's strong brand portfolio, including Pampers, its flagship baby-care product, is expected to continue driving revenue and profit growth.